It is common in medicine to titrate therapy according to target ranges of 
objectively measured parameters. Objective measurement of motor function is 
available for Parkinson's Disease (PD), making it possible to optimise therapy 
and clinical outcomes. In this study, an accelerometry based measurement and 
predefined target ranges were used to assess motor function in a Northern 
Tasmania PD cohort managed by a Movement Disorder clinic. Approximately 40% 
(n = 103) of the total PD population participated in this study and motor scores 
were within target in 22%. In the 78% above target, changes in oral therapy were 
recommended in 74%, Advanced Therapy in 12% and treatment was contraindicated in 
9%. Following changes in oral therapy, there was a further objective measurement 
and clinical consultation to establish whether scores had reached target range: 
if so subjects left the study, otherwise further changes of therapy were 
recommended (unless contraindications were present). Seventy-seven cases 
completed the study, with 48% achieving target (including 22% at outset), 
Advanced Therapy recommended in 19% and contraindications preventing any change 
in therapy in 17%. In the 43% of cases in whom oral therapy was changed, total 
UPDRS improved significantly (effect size = 8) as did the PDQ39 in cases 
reaching target. NMS Quest and MOCA scores also improved significantly. This 
study shows that many people in a representative cohort of PD would benefit from 
objective assessment and treatment of their PD features against a target.